MX2015008010A - Compuestos radiosensabilizadores para usarse en combinacion con radiacion. - Google Patents

Compuestos radiosensabilizadores para usarse en combinacion con radiacion.

Info

Publication number
MX2015008010A
MX2015008010A MX2015008010A MX2015008010A MX2015008010A MX 2015008010 A MX2015008010 A MX 2015008010A MX 2015008010 A MX2015008010 A MX 2015008010A MX 2015008010 A MX2015008010 A MX 2015008010A MX 2015008010 A MX2015008010 A MX 2015008010A
Authority
MX
Mexico
Prior art keywords
combination
radiosensitizer compounds
radiation
radiosensitizer
disclosed
Prior art date
Application number
MX2015008010A
Other languages
English (en)
Spanish (es)
Inventor
qing-bin Lu
Original Assignee
qing-bin Lu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by qing-bin Lu filed Critical qing-bin Lu
Publication of MX2015008010A publication Critical patent/MX2015008010A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C211/44—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring
    • C07C211/52—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2015008010A 2012-12-20 2013-12-20 Compuestos radiosensabilizadores para usarse en combinacion con radiacion. MX2015008010A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261797983P 2012-12-20 2012-12-20
PCT/CA2013/051005 WO2014094178A1 (en) 2012-12-20 2013-12-20 Radiosensitizer compounds for use in combination with radiation

Publications (1)

Publication Number Publication Date
MX2015008010A true MX2015008010A (es) 2016-04-26

Family

ID=50977492

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015008010A MX2015008010A (es) 2012-12-20 2013-12-20 Compuestos radiosensabilizadores para usarse en combinacion con radiacion.

Country Status (10)

Country Link
US (1) US9655965B2 (enExample)
EP (1) EP2935215B1 (enExample)
JP (1) JP6321673B2 (enExample)
KR (1) KR102278760B1 (enExample)
CN (1) CN105164107B (enExample)
AU (1) AU2013362757B2 (enExample)
BR (1) BR112015014855A2 (enExample)
CA (1) CA2895526C (enExample)
MX (1) MX2015008010A (enExample)
WO (1) WO2014094178A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102307387B1 (ko) 2013-10-08 2021-09-30 큉-빈 루 표적화된 화학요법에 사용하기 위한 비­백금­기반 항암 화합물
JP6927882B2 (ja) * 2015-04-02 2021-09-01 プロキシマジェン,リミティド ライアビリティ カンパニー 癌の新治療法
CN106045932B (zh) * 2016-06-06 2018-05-15 浙江省肿瘤医院 一种具有放射增敏作用的化合物及其应用
JP6955243B2 (ja) * 2017-02-24 2021-10-27 学校法人北里研究所 ネクローシスの検出キット及びその使用
JP7098054B2 (ja) * 2018-05-30 2022-07-08 ファロス・アイバイオ・カンパニー・リミテッド 2,3,5-置換されたチオフェン化合物の放射線治療増進用途
WO2021224186A1 (en) * 2020-05-04 2021-11-11 Institut Curie New pyridine derivatives as radiosensitizers
CN114478524A (zh) * 2022-03-15 2022-05-13 江苏省肿瘤医院 1,8-萘啶类化合物及其应用
CN114560799A (zh) * 2022-03-15 2022-05-31 江苏省肿瘤医院 腈基取代苯基类化合物及其应用
CN120501862B (zh) * 2025-07-18 2025-10-10 四川大学华西医院 一种能够放射增敏和防护放射性损伤的双效化合物、包含其的组合物及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5011451B1 (enExample) * 1969-05-05 1975-05-01
GB1363735A (en) * 1970-10-23 1974-08-14 Hoechst Ag Process for the manufacture of benzimidazolones
US3822261A (en) * 1972-10-30 1974-07-02 Dow Chemical Co 5,6-dihalo-2-fluoroalkyl-1h-imidazo(4,5-b)pyrazines
GR72941B (enExample) * 1978-10-20 1984-01-16 Lilly Co Eli
US4210647A (en) * 1979-06-18 1980-07-01 Eli Lilly And Company Antiviral combinations
JPS597175A (ja) * 1982-07-01 1984-01-14 メルク・エンド・カムパニ−・インコ−ポレ−テツド 放射線治療用添加剤として有用な、クロロニトロアミノピラジン及びアルキルアミノピラジンのアミノとアミド誘導体
GB8722488D0 (en) * 1987-09-24 1987-10-28 Fujisawa Pharmaceutical Co Imidazopyridine compound
DK0647137T3 (da) * 1992-06-22 2008-12-08 State Of Oregon Through Oregon Glycinreceptorantagonister og anvendelse deraf
IL112235A (en) * 1994-01-03 2000-06-29 Acea Pharm Inc 1,4-dihydro-pyrido¬2,3-b¾pyrazine-2,3-dione (5 or 8) oxide derivatives and pharmaceutical compositions containing them
US5753687A (en) * 1995-06-19 1998-05-19 Ontogen Corporation Modulators of proteins with phosphotryrosine recognition units
JP2003520271A (ja) * 2000-01-24 2003-07-02 メルク エンド カムパニー インコーポレーテッド αvインテグリン受容体拮抗薬
US6538010B1 (en) * 2000-11-08 2003-03-25 Research Triangle Institute Compounds and methods for promoting smoking cessation
GB0428082D0 (en) 2004-12-22 2005-01-26 Welcome Trust The Ltd Therapeutic compounds
CN101155782B (zh) * 2005-04-01 2011-05-04 大鹏药品工业株式会社 以吡啶衍生物为有效成分的放射线治疗增强剂
WO2006106984A1 (ja) * 2005-04-01 2006-10-12 Taiho Pharmaceutical Co., Ltd. ピリジン誘導体を有効成分とする放射線治療増強剤
JP2010500372A (ja) * 2006-08-09 2010-01-07 スミスクライン ビーチャム コーポレーション オピオイド受容体に対するアンタゴニストまたはインバースアゴニストとしての新規化合物
CA2663856A1 (en) 2006-09-28 2008-04-10 Exelixis, Inc. Jak-2 modulators and methods of use
CN101611007A (zh) * 2006-12-20 2009-12-23 先灵公司 新颖的jnk抑制剂
KR101712576B1 (ko) * 2008-11-10 2017-03-06 버텍스 파마슈티칼스 인코포레이티드 Atr 키나제의 억제제로서 유용한 화합물
WO2011026219A1 (en) * 2009-09-01 2011-03-10 Lu qing-bin Combination therapy for cancer comprising a platinum -based antineoplastic agent and a biocompatible electron donor
US8962631B2 (en) * 2010-05-12 2015-02-24 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
GB201017345D0 (en) * 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists

Also Published As

Publication number Publication date
BR112015014855A2 (pt) 2017-07-11
US9655965B2 (en) 2017-05-23
CA2895526C (en) 2021-08-24
EP2935215B1 (en) 2019-11-13
JP6321673B2 (ja) 2018-05-09
CN105164107A (zh) 2015-12-16
KR20150120953A (ko) 2015-10-28
WO2014094178A1 (en) 2014-06-26
AU2013362757A1 (en) 2015-07-30
EP2935215A1 (en) 2015-10-28
JP2016504325A (ja) 2016-02-12
EP2935215A4 (en) 2016-10-26
AU2013362757B2 (en) 2018-06-14
US20150343059A1 (en) 2015-12-03
KR102278760B1 (ko) 2021-07-20
CN105164107B (zh) 2017-12-05
CA2895526A1 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
CA2871471C (en) Dna-pk inhibitors
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
WO2012104007A3 (de) 7-azaindolderivate
MX349004B (es) Nuevos compuestos.
MD20140002A2 (ro) Indazoli
IN2012DN02081A (enExample)
PH12013500299B1 (en) Pyrrolopyrimidine compounds and uses thereof
PH12013501600A1 (en) Novel heterocyclic derivatives
MX2014013090A (es) Derivados de pirrolotriazinona.
PH12015501609A1 (en) Phenicol antibacterials
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
MX362855B (es) Derivados de quinazolinona como inhidores poli (adp-ribosa) polimerasa (parp).
UA112795C2 (uk) Біциклічні піразинонові похідні
PH12014501967A1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
WO2013061004A8 (fr) Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines
GB201209587D0 (en) Therapeutic compounds
MX340574B (es) Imidazo pirazinas.
MX2013011124A (es) Compuestos para el tratamiento del sindrome metabolico.
AU2012240222A8 (en) Methods of treating central nervous system tumors
WO2014035846A3 (en) Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
PH12013500275A1 (en) Novel trpv3 modulators
MX2016008042A (es) Derivados de imidazopirazinona.
MX365192B (es) Derivados de bendamustina y compuestos relacionados, y uso medico de los mismos para la terapia de cancer.
NZ629475A (en) Pharmaceutical composition comprising benzyl alcohol for the treatment of migraines